ENLIVEN THERAPEUTICS INC (ELVN) Stock Fundamental Analysis

NASDAQ:ELVN • US29337E1029

26.37 USD
+0.24 (+0.92%)
At close: Feb 18, 2026
26.37 USD
0 (0%)
After Hours: 2/18/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall ELVN gets a fundamental rating of 3 out of 10. We evaluated ELVN against 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability. ELVN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ELVN had negative earnings in the past year.
  • In the past year ELVN has reported a negative cash flow from operations.
  • In the past 5 years ELVN reported 4 times negative net income.
  • ELVN had a negative operating cash flow in each of the past 5 years.
ELVN Yearly Net Income VS EBIT VS OCF VS FCFELVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • ELVN has a Return On Assets of -19.80%. This is in the better half of the industry: ELVN outperforms 60.73% of its industry peers.
  • ELVN has a Return On Equity of -20.42%. This is in the better half of the industry: ELVN outperforms 68.06% of its industry peers.
Industry RankSector Rank
ROA -19.8%
ROE -20.42%
ROIC N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ELVN Yearly ROA, ROE, ROICELVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • ELVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELVN Yearly Profit, Operating, Gross MarginsELVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ELVN has been increased compared to 1 year ago.
  • Compared to 5 years ago, ELVN has more shares outstanding
  • There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELVN Yearly Shares OutstandingELVN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ELVN Yearly Total Debt VS Total AssetsELVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 63.13 indicates that ELVN is not in any danger for bankruptcy at the moment.
  • ELVN has a better Altman-Z score (63.13) than 96.86% of its industry peers.
  • There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.13
ROIC/WACCN/A
WACCN/A
ELVN Yearly LT Debt VS Equity VS FCFELVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 32.95 indicates that ELVN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 32.95, ELVN belongs to the best of the industry, outperforming 96.34% of the companies in the same industry.
  • A Quick Ratio of 32.95 indicates that ELVN has no problem at all paying its short term obligations.
  • The Quick ratio of ELVN (32.95) is better than 96.34% of its industry peers.
Industry RankSector Rank
Current Ratio 32.95
Quick Ratio 32.95
ELVN Yearly Current Assets VS Current LiabilitesELVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 3.16% over the past year.
EPS 1Y (TTM)3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELVN will show a small growth in Earnings Per Share. The EPS will grow by 4.29% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.86%
EPS Next 2Y-2.95%
EPS Next 3Y-12.9%
EPS Next 5Y4.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELVN Yearly Revenue VS EstimatesELVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ELVN Yearly EPS VS EstimatesELVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELVN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELVN Price Earnings VS Forward Price EarningsELVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELVN Per share dataELVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • A cheap valuation may be justified as ELVN's earnings are expected to decrease with -12.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.95%
EPS Next 3Y-12.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ELVN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (2/18/2026, 8:00:01 PM)

After market: 26.37 0 (0%)

26.37

+0.24 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-12
Inst Owners87.65%
Inst Owner Change0.96%
Ins Owners8.3%
Ins Owner Change4.58%
Market Cap1.57B
Revenue(TTM)N/A
Net Income(TTM)-97.21M
Analysts85
Price Target41.59 (57.72%)
Short Float %17.03%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.85%
Min EPS beat(2)10.02%
Max EPS beat(2)27.67%
EPS beat(4)3
Avg EPS beat(4)10.11%
Min EPS beat(4)-10.75%
Max EPS beat(4)27.67%
EPS beat(8)7
Avg EPS beat(8)11.77%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.82%
EPS NY rev (1m)0%
EPS NY rev (3m)10.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.29
P/tB 3.29
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS8.02
TBVpS8.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.8%
ROE -20.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.29%
ROA(5y)-32.18%
ROE(3y)-18.6%
ROE(5y)-34.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.95
Quick Ratio 32.95
Altman-Z 63.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)30.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y6.86%
EPS Next 2Y-2.95%
EPS Next 3Y-12.9%
EPS Next 5Y4.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.26%
EBIT Next 3Y-25.46%
EBIT Next 5YN/A
FCF growth 1Y-18.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.58%
OCF growth 3YN/A
OCF growth 5YN/A

ENLIVEN THERAPEUTICS INC / ELVN FAQ

What is the fundamental rating for ELVN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELVN.


What is the valuation status of ENLIVEN THERAPEUTICS INC (ELVN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENLIVEN THERAPEUTICS INC (ELVN). This can be considered as Overvalued.


How profitable is ENLIVEN THERAPEUTICS INC (ELVN) stock?

ENLIVEN THERAPEUTICS INC (ELVN) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ELVN stock?

The Earnings per Share (EPS) of ENLIVEN THERAPEUTICS INC (ELVN) is expected to grow by 6.86% in the next year.